Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALN-PNP in NAFLD with PNPLA3 Genetic Risk Factor
NCT06024408Phase 1Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- May 2024
- Primary completion
- Jul 2025
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of pivicasiran in non-alcoholic fatty liver disease (NAFLD), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Incidence of treatment-emergent adverse events up to 253 days and Severity of treatment-emergent adverse events up to 253 days. Started May 2024; status: completed.
02
Drugs
pivicasiran
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT06024408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06024408.